Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.0%

7 terminated out of 87 trials

Success Rate

80.6%

-6.0% vs benchmark

Late-Stage Pipeline

17%

15 trials in Phase 3/4

Results Transparency

21%

6 of 29 completed with results

Key Signals

6 with results81% success

Data Visualizations

Phase Distribution

63Total
Not Applicable (26)
Early P 1 (1)
P 1 (6)
P 2 (15)
P 3 (10)
P 4 (5)

Trial Status

Completed29
Recruiting20
Unknown18
Not Yet Recruiting8
Terminated7
Active Not Recruiting2

Trial Success Rate

80.6%

Benchmark: 86.6%

Based on 29 completed trials

Clinical Trials (87)

Showing 20 of 20 trials
NCT07131696Not ApplicableRecruitingPrimary

The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

NCT06443177Not ApplicableSuspended

The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

NCT06288659Not ApplicableActive Not RecruitingPrimary

aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial

NCT07652749Not ApplicableNot Yet RecruitingPrimary

Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage

NCT03754335Not ApplicableCompletedPrimary

SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture

NCT07614906RecruitingPrimary

Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage

NCT05491980Active Not Recruiting

Florida Cerebrovascular Disease Biorepository and Genomics Center

NCT07250958RecruitingPrimary

Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage

NCT06284642Phase 4RecruitingPrimary

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

NCT05738083RecruitingPrimary

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH

NCT07493577Phase 1Not Yet RecruitingPrimary

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

NCT06863480Phase 1RecruitingPrimary

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

NCT06494436Recruiting

Microvention AnEurysm & STroke Real-life Data cOllection

NCT06409364Phase 2RecruitingPrimary

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

NCT07270419RecruitingPrimary

Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program

NCT04566991Phase 2RecruitingPrimary

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT06352593Not ApplicableCompleted

Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage

NCT07249853Phase 3Not Yet RecruitingPrimary

Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

NCT01779713CompletedPrimary

Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage

NCT01095731Phase 2CompletedPrimary

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Scroll to load more

Research Network

Activity Timeline